Nektar Therapeutics NKTR

Updated: 8 Aug 2026

NASDAQ | Biotech | Biotechnology and immunotherapy

No signal published yet

We already track Nektar Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Nektar Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology and immunotherapy
We're already tracking Nektar Therapeutics — here are the latest events we've registered

Recent News

  • On July 21, 2026, Nektar Therapeutics announced the initiation of the Phase 3 ZENITH-AD program evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis. The company also announced on July 28, 2026, that it will report its second-quarter 2026 financial results on August 13, 2026.

What Firelda Watch includes for Nektar Therapeutics

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Nektar Therapeutics will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Xbrane Biopharma AB (publ)
XBRANE
HOLD
SynAct Pharma AB
SYNACT
HOLD

Biotech

More companies in this sector

Want to follow Nektar Therapeutics? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Nektar Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Nektar Therapeutics NKTR
Nektar Therapeutics — follow and we'll monitor it
Follow Nektar Therapeutics free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.